Significance of FDA's Expedited Generic Drug Application Final Approval

The U.S. Food and Drug Administration (FDA) has granted final approval for Rising Pharma Holdings, Inc.'s abbreviated new drug application (ANDA 217995) for gabapentin 600mg and 800mg tablets. This approval involves a structure where Graviti Pharmaceuticals, an Indian manufacturing partner, produces the drug, and Rising Pharma handles distribution within the U.S. This is more than just an administrative registration; it marks a crucial turning point in strengthening Rising Pharma's position in the rapidly growing U.S. generic neurological market. Specifically, it provides a direct platform to significantly increase market share by leveraging price competitiveness against the original drug, Neurontin, from Pfizer.

Mechanism of Action and Clinical Indications of Gabapentin

Gabapentin works by binding to the α2δ subunit of voltage-gated calcium channels in the central nervous system (CNS), inhibiting the release of excitatory neurotransmitters. It is widely prescribed as an adjunct therapy for managing postherpetic neuralgia (PHN) in adults and for partial-onset seizures in children aged 3 years and older, as well as adults. Supplying high-quality generics for chronic pain patients who require long-term treatment significantly improves treatment accessibility and reduces the economic burden. This aligns perfectly with the latest trend of increasing preference for non-opioid analgesics.

U.S. Neurological Drug Market Size and Opportunities for Rising Pharma

As of 2025, the U.S. gabapentin market is valued at approximately $680 million (approximately 900 billion Korean Won), making it the largest consumer market, accounting for more than 30% of the global market. The 600mg and 800mg high-dose tablet formulations, which have received approval, are likely to rapidly replace the existing capsule-based market by improving patient convenience. With strong support from private equity firm H.I.G. Capital, Rising Pharma is expected to pursue aggressive pricing strategies based on a highly efficient overseas supply chain. This will enable the company to gain an advantage in contracts with price-sensitive large U.S. distribution networks (GPOs) and pharmacy chains, generating significant revenue in a short period.

Intensifying Generic Competition and the Importance of Supply Chain Management

The U.S. gabapentin market is currently a highly competitive red ocean, with multinational generic companies such as Teva, Lupin, and Apotex vying for market share. In this environment of extreme margin pressure, organic management of the supply chain, with Graviti Pharmaceuticals responsible for supplying Indian active pharmaceutical ingredients (APIs) and manufacturing finished pharmaceutical products, is key to survival. In contrast to the recent voluntary recall issue with other products, the gabapentin production line has demonstrated strict compliance with current good manufacturing practice (cGMP) standards, mitigating regulatory risks. Rising Pharma aims to secure prescription trust and counter competitors by demonstrating stable quality assurance and timely supply capabilities.